<DOC>
	<DOCNO>NCT02688023</DOCNO>
	<brief_summary>Colorectal cancer aggressive malignancy poor overall outcome . The purpose study evaluate feasibility , safety efficacy neoadjuvant oxaliplatin , irinotecan combine 5-fluorouraci/leucovorin S-1 capecitabine patient resectable colorectal cancer .</brief_summary>
	<brief_title>Neoadjuvant Triplet Chemotherapy Regimen Patients With Resectable Colorectal Cancer</brief_title>
	<detailed_description>This single arm , phase 2 study neoadjuvant triplet chemotherapy regimen oxaliplatin , irinotecan combine 5-fluorouraci/leucovorin S-1 capecitabine patient resectable colorectal cancer.Fifty patient enrol trial . The primary objective study determine 3-year disease-free survival patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically verified colorectal cancer clinical stage T4N02M0„ÄÅcT13N2M0 M1 ( liver metastasis ) age : 1870 year ECOG 02 adequate bone marrow , liver , renal cardiac function ( history ischemic heart disease ) prior cancer and/or chemotherapy sign informed consent patient history prior malignancy pregnant lactating patient know suspected brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>5-fluorouracil</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>chemotherapy</keyword>
</DOC>